Literature DB >> 22305478

Dispersible amyloid β-protein oligomers, protofibrils, and fibrils represent diffusible but not soluble aggregates: their role in neurodegeneration in amyloid precursor protein (APP) transgenic mice.

Ajeet Rijal Upadhaya1, Estibaliz Capetillo-Zarate, Irina Kosterin, Dorothee Abramowski, Sathish Kumar, Haruyasu Yamaguchi, Jochen Walter, Marcus Fändrich, Matthias Staufenbiel, Dietmar Rudolf Thal.   

Abstract

Soluble amyloid β-protein (Aβ) aggregates have been identified in the Alzheimer's disease (AD) brain. Dispersed Aβ aggregates in the brain parenchyma are different from soluble, membrane-associated and plaque-associated solid aggregates. They are in mixture with the extra- or intracellular fluid but can be separated from soluble proteins by ultracentrifugation. To clarify the role of dispersible Aβ aggregates for neurodegeneration we analyzed 2 different amyloid precursor protein (APP)-transgenic mouse models. APP23 mice overexpress human mutant APP with the Swedish mutation. APP51/16 mice express high levels of human wild type APP. Both mice develop Aβ-plaques. Dendritic degeneration, neuron loss, and loss of asymmetric synapses were seen in APP23 but not in APP51/16 mice. The soluble and dispersible fractions not separated from one another were received as supernatant after centrifugation of native forebrain homogenates at 14,000 × g. Subsequent ultracentrifugation separated the soluble, i.e., the supernatant, from the dispersible fraction, i.e., the resuspended pellet. The major biochemical difference between APP23 and APP51/16 mice was that APP23 mice exhibited higher levels of dispersible Aβ oligomers, protofibrils and fibrils precipitated with oligomer (A11) and protofibril/fibril (B10AP) specific antibodies than APP51/16 mice. These differences, rather than soluble Aβ and Aβ plaque pathology were associated with dendritic degeneration, neuron, and synapse loss in APP23 mice in comparison with APP51/16 mice. Immunoprecipitation of dispersible Aβ oligomers, protofibrils, and fibrils revealed that they were associated with APP C-terminal fragments (APP-CTFs). These results indicate that dispersible Aβ oligomers, protofibrils, and fibrils represent an important pool of Aβ aggregates in the brain that critically interact with membrane-associated APP C-terminal fragments. The concentration of dispersible Aβ aggregates, thereby, presumably determines its toxicity.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22305478     DOI: 10.1016/j.neurobiolaging.2011.12.032

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  25 in total

Review 1.  Molecular Signaling Mechanisms of Natural and Synthetic Retinoids for Inhibition of Pathogenesis in Alzheimer's Disease.

Authors:  Mrinmay Chakrabarti; Alexander J McDonald; J Will Reed; Melissa A Moss; Bhaskar C Das; Swapan K Ray
Journal:  J Alzheimers Dis       Date:  2016       Impact factor: 4.472

2.  Maturation of neuronal AD-tau pathology involves site-specific phosphorylation of cytoplasmic and synaptic tau preceding conformational change and fibril formation.

Authors:  Luis Aragão Gomes; Valerie Uytterhoeven; Diego Lopez-Sanmartin; Sandra O Tomé; Thomas Tousseyn; Rik Vandenberghe; Mathieu Vandenbulcke; Christine A F von Arnim; Patrik Verstreken; Dietmar Rudolf Thal
Journal:  Acta Neuropathol       Date:  2021-01-11       Impact factor: 17.088

Review 3.  The β-secretase (BACE) inhibitor NB-360 in preclinical models: From amyloid-β reduction to downstream disease-relevant effects.

Authors:  Ulf Neumann; Rainer Machauer; Derya R Shimshek
Journal:  Br J Pharmacol       Date:  2019-03-10       Impact factor: 8.739

Review 4.  Senescence-accelerated OXYS rats: a model of age-related cognitive decline with relevance to abnormalities in Alzheimer disease.

Authors:  Natalia A Stefanova; Oyuna S Kozhevnikova; Anton O Vitovtov; Kseniya Yi Maksimova; Sergey V Logvinov; Ekaterina A Rudnitskaya; Elena E Korbolina; Natalia A Muraleva; Nataliya G Kolosova
Journal:  Cell Cycle       Date:  2014-02-17       Impact factor: 4.534

Review 5.  Amyloid β precursor protein as a molecular target for amyloid β--induced neuronal degeneration in Alzheimer's disease.

Authors:  Elena Anahi Bignante; Florencia Heredia; Gerardo Morfini; Alfredo Lorenzo
Journal:  Neurobiol Aging       Date:  2013-05-25       Impact factor: 4.673

Review 6.  Potential mechanisms and implications for the formation of tau oligomeric strains.

Authors:  Julia E Gerson; Amrit Mudher; Rakez Kayed
Journal:  Crit Rev Biochem Mol Biol       Date:  2016-09-21       Impact factor: 8.250

7.  Discrete Pools of Oligomeric Amyloid-β Track with Spatial Learning Deficits in a Mouse Model of Alzheimer Amyloidosis.

Authors:  Angie C A Chiang; Stephanie W Fowler; Rohit Reddy; Olga Pletnikova; Juan C Troncoso; Mathew A Sherman; Sylvain E Lesne; Joanna L Jankowsky
Journal:  Am J Pathol       Date:  2017-12-15       Impact factor: 4.307

8.  When amyloids become prions.

Authors:  Raimon Sabate
Journal:  Prion       Date:  2014-05-15       Impact factor: 3.931

9.  Pathology of clinical and preclinical Alzheimer's disease.

Authors:  Dietmar Rudolf Thal; Christine von Arnim; W Sue T Griffin; Haruyasu Yamaguchi; Robert E Mrak; Johannes Attems; Ajeet Rijal Upadhaya
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-11       Impact factor: 5.270

10.  Impact of amyloid β aggregate maturation on antibody treatment in APP23 mice.

Authors:  Karthikeyan Balakrishnan; Ajeet Rijal Upadhaya; Julia Steinmetz; Julia Reichwald; Dorothee Abramowski; Marcus Fändrich; Sathish Kumar; Haruyasu Yamaguchi; Jochen Walter; Matthias Staufenbiel; Dietmar Rudolf Thal
Journal:  Acta Neuropathol Commun       Date:  2015-07-04       Impact factor: 7.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.